الفهرس 
Introduction
Hepatitis C virus natureOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
DAAs made revolutionary improvement in HCV treatment. Its efficacy expressed as sustained virological response and safety special patient groups was marked. However, the data available regarding the effect of DAAs in chronic HCV patients on normal kidneys functions are few.This study was conducted to determine the effect of different direct acting antiviral drug regimens used for treatment of chronic HCV infected patients on normal kidneys function. To assess that, clinical, hematological parameters and liver and kidneys function tests were performed plus measuring urinary NGAL response to DAAs therapy and SVR. The current research planned to investigate the safety of DAAs on normal kidney. One hundred chronic HCV patients who were planned to be treated with DAAs were enrolled in this study. They were divided into three groups, group (1) included 40 patients who were treated with combination of Sofosbuvir and Daclatasvir with or without ribavirin. while group (2) included 31 patients who received combination of ombitasvir, paritaprevir and ritonavir in one single tablet with ribavirin and group (3) included 29 patients receiving combination of Sofosbuvir and Ledipasvir with or without ribavirin. The results of the present study showed that: The three DAA regimens were effective as they achieved excellent rates of viral clearance. Hematological tests findings and Liver functions did not make significant change before therapy within groups neither after therapy as most of them were in the normal range so no improvement was hoped for. Albumin/creatinine ratio increased significantly after therapy in the group received SOF/Dacla and SOF/Ledi indicating renal pathology due to treatment with SOF.A relatioship was found between urinary NGAL and albumin/creatinine ratio as uNGAL increased significantly after 12 weeks treatment in SOF/Dacla and SOF/Ledi groups indicating renal tubular damage as a consequence of SOF administration. Albumin /creatinine ratio and uNGAL in the second group took ombitasvir, paritaprevir and ritonavir showed no significant change indicating their renal safety.